Proteomics Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines population proteomics, the measurement of thousands of proteins in blood samples from very large groups of people, linked to health records and genetics. It tests how fast these programmes move from pilots into routine population health research and risk prediction, and which participants capture value among platform developers, sequencing and tools suppliers, pharmaceutical sponsors and biobanks.

Scale is the defining change. The pilot of the UK Biobank Pharma Proteomics Project, reported in Nature in October 2023, measured about 3,000 proteins in more than 54,000 participants. In January 2025 the follow-on programme was announced with a first phase of 300,000 samples, drawing on a consortium of pharmaceutical companies. The conclusion is that a single programme now exceeds earlier protein studies by a factor of several, which gives drug developers protein data at the scale already available for genetics.

The measurement chain has changed as well. The Olink platform, owned by Thermo Fisher Scientific, reads protein levels through DNA tags that are counted by sequencing, and the programme draws on sequencing from Ultima Genomics and analysis from the Regeneron Genetics Center. The conclusion is that population proteomics now depends on sequencing capacity as much as on assay chemistry, which ties its cost to the cost of sequencing.

Competing platforms were assessed for the programme and were not selected, which shows that the choice of a first large scale platform is still contested. SomaScan, now part of Illumina, and mass spectrometry methods from Bruker, Thermo Fisher Scientific and Danaher remain in use in other cohorts. The conclusion is that no single method yet defines the field, and the winner in each study depends on proteins covered, cost per sample and compatibility with earlier data.

Cost and clinical validation are the restraints. Consumables for hundreds of thousands of samples are a large budget item, results differ between platforms for some proteins, and few protein signatures have been validated for clinical use. The conclusion is that near term growth comes from research and drug development budgets, and clinical use depends on validation studies that take years.

The brief treats population proteomics as an accelerating category with a nine year horizon to 2035. It identifies which applications, regions and operators scale first and what each means for platform developers, sequencing and tools suppliers, pharmaceutical sponsors and biobanks. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Population proteomics measures the levels of thousands of proteins in blood plasma from large cohorts, so that protein patterns can be linked to disease, genetics and outcomes.

Affinity methods use antibodies or aptamers to capture proteins, and the Olink proximity extension assay converts each protein into a DNA barcode read by sequencing. SomaScan uses aptamers, and mass spectrometry identifies proteins by mass and fragmentation.

Newer approaches include single molecule protein sequencing and nanoparticle based enrichment of plasma, which aim to cover more proteins with less sample.

Uses are target validation for drugs, biomarker discovery, risk prediction, patient stratification and studies of ageing, each under research or laboratory test rules.

The limits are consumable cost at scale, differences between platforms, data volume, and limited clinical validation of protein signatures. The period turns on whether lower cost per sample and validation studies lead protein tests into clinical practice.

The population proteomics market, covering affinity and mass spectrometry platforms, consumables, sequencing readout, software and analysis services used in biobank and population health research, is valued at USD 1.5–2.5 billion in 2026 and is projected to reach USD 6.16–10.27 billion by 2035, at a CAGR of 17%.

The 2026 base rests on platforms, consumables, sequencing readout, software and analysis services sold to biobanks, pharmaceutical sponsors, research institutes and laboratories. Growth then follows biobank programme launches, falling cost per sample and the first clinical uses.

The forecast is sensitive to cost per sample, the number of large cohorts funded and clinical validation. Regionally, Europe leads through the UK Biobank programme, North America on platform developers and pharmaceutical sponsors, and Asia-Pacific on cohorts in China and Japan.

The base case assumes cost per sample falls steadily and several biobanks launch programmes of 100,000 or more samples, giving the inflection in 2031. An accelerated case assumes clinical validation of protein risk scores and early coverage, bringing the inflection to 2029 and lifting the 2035 value to the top of the range. A delayed case assumes tight research budgets and slow validation, holding growth at the bottom of the range.

Growth drivers

• Biobank proteomics programmes.
• Pharmaceutical use in target validation and biomarkers.
• Falling cost per sample.
• Extension to diagnostics and risk prediction.

Enablers

• Pharmaceutical consortium funding.
• Vendor and biobank partnerships.
• Sequencing and compute capacity.
• Cloud research platforms.

Restraints and barriers

• Consumable cost at scale.
• Differences between platforms.
• Data volume and analysis burden.
• Limited clinical validation of protein signatures.

The direction of population proteomics is set by the need for protein level evidence in population research, standards and regulation, new assays and platforms, biobank, pharmaceutical and vendor partnering, and sequencing capacity and cost per sample.

The key participants in population proteomics include Thermo Fisher Scientific Inc., Illumina, Inc., Ultima Genomics, Inc., Regeneron Pharmaceuticals, Inc., Bruker Corporation, Danaher Corporation, Agilent Technologies, Inc., Waters Corporation, Quantum-Si Incorporated, Nautilus Biotechnology, Inc., Seer, Inc., Alamar Biosciences, Inc., Biognosys AG, Evotec SE, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Element Biosciences, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, F. Hoffmann-La Roche Ltd, UK Biobank, University of Oxford, Wellcome Sanger Institute, Broad Institute, Karolinska Institutet, Estonian Biobank, China Kadoorie Biobank, All of Us Research Program, Human Proteome Organization, Global Alliance for Genomics and Health, Medical Research Council, National Institutes of Health, U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, Medicines and Healthcare products Regulatory Agency, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency, European Commission, Clinical and Laboratory Standards Institute and College of American Pathologists.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as population proteomics matures.

Thermo Fisher Scientific leads on affinity platforms through Olink, Illumina holds SomaScan, Bruker, Danaher and Agilent Technologies compete in mass spectrometry, and Ultima Genomics and Element Biosciences supply sequencing readout. Quantum-Si, Nautilus and Seer pursue newer methods, and Laboratory Corporation of America Holdings and Quest Diagnostics hold the clinical laboratory channel. Competitive intensity is high in 2026 and rises as programmes widen.

Where value migrates.

In 2026 value sits with platform developers that offer large panels at low cost per sample and with sequencing suppliers whose capacity sets that cost, because the buyers are research budgets that pay for proteins measured. By 2031 it moves toward companies with validated protein risk and biomarker products, because clinical buyers pay for a decision, not a data point. By 2035 it settles in integrated proteomic, sequencing and analysis platforms that sell a result. Margins hold for platforms with broad panels and analysis software and narrow for commodity measurement.

The signals converge on scale and falling cost per sample. A pilot of more than 54,000 participants was followed by a programme of 300,000 samples, and sequencing based readout ties cost to sequencing prices. Each signal supports growth, and platform differences and clinical validation limit the pace.

Structural limits show where progress could slow: consumable cost at scale, differences between platforms, data volume, and limited clinical validation of protein signatures. The brief therefore tracks four indicators: cost per sample, samples profiled in biobank programmes, validated protein risk tools, and regulatory and coverage decisions.

Drug target validation first, then biomarker panels and risk scores, then clinical diagnostics and screening are the expected order of adoption.